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Proline-, glutamic acid-, and leucine-rich protein (PELP)1, also known as modulator of nongenomic actions
of the estrogen receptor (MNAR), is a novel nuclear receptor coregulator with a multitude of functions.
PELP1/MNAR serves as a scaffolding protein that couples various signaling complexes with nuclear receptors
and participates in genomic and nongenomic functions. Recent data suggest that PELP1/MNAR expression
is deregulated in several cancers, including breast, endometrial, prostate, and ovarian cancer, and that
PELP1/MNAR interacts with several oncogenes. In this review, we summarize the emerging biological properties
and functions of PELP1/MNAR.
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Introduction
Researchers first identified proline-, glutamic acid-, and
leucine-rich protein (PELP)1, as one of the several
proteins that bind to the SH2 domain of Lck tyrosine
protein kinase utilizing GST-SH2 pull down assays. In
the SDS-Page gel this protein migrated as a 160-kDa
protein, hence it was initially named p160 (not to be
confused with the SRC/p160 family) (Figure 1 and [Joung
et al., 1996]). Using peptide sequences derived from the
purified 160-kDa protein as oligonucleotide probes,
investigators cloned two cDNAs of different lengths:
PELP1 and PELP2 [Vadlamudi et al., 2001]. Initial studies
using the longer clone, PELP1 (3.8 kb), resulted in
generation of a 160-kDa protein product and identification
of coactivator activity for ERα transactivation [Vadlamudi
et al., 2001]. Subsequent studies using ERα affinity
chromatography identified a protein that is identical to
PELP1 at the amino acid level, but differs slightly in cDNA
length (3.4 kb).Therefore, researchers presumed that
this was a new protein and named it modulator of
nongenomic actions of estrogen receptor (MNAR) [Wong
et al., 2002]. However, both the PELP1 and MNAR gene
sequences map to the same chromosomal region,
17p13.2, and have identical sequences except for an
additional 435-bp region in PELP1 [Balasenthil and
Vadlamudi, 2003]. Further analysis of the PELP1 cDNA
regions in 3.8 kb PELP1 suggested that the initially
isolated PELP1 cDNA was an immature transcript and
contained an extra 435-bp intron with consensus splice
sites that artificially produced the disparity in length
between the PELP1 and MNAR cDNAs. Later studies
showed that PELP1 and MNAR code for the same
proteins, and several studies reported that PELP1 and
MNAR are identical proteins. HUGO Gene Nomenclature
Committee (HGNC) approved PELP1 as the approved
symbol for PELP1/MNAR. Functional studies revealed
that in addition to Lck, PELP1/MNAR also interacts with
other members of the Src kinase family, including c-Src
[Wong et al., 2002]. Subsequent studies identified
orthologs to PELP1/MNAR in mice and rats [Khan et al.,
2005]. Homology data established that PELP1/MNAR is
expressed in other mammals, including chimpanzees,
dogs, and cats. A previous study also reported on a cDNA
encoding Xenopus PELP1/MNAR [Haas et al., 2005].
Protein domain structure
PELP1/MNAR contains several motifs and domains that
are commonly present in many transcriptional
coactivators, including 10 nuclear receptor
(NR)-interacting boxes (LXXLL motifs), a zinc finger, a
glutamic acid-rich domain, and 2 proline-rich domains
(Figure 1 and [Vadlamudi et al., 2001;Wong et al., 2002]).
A unique feature of PELP1/MNAR is the presence of an
unusual stretch of 70 acidic amino acids in the C-terminus
that functions as a histone-binding region [Choi et al.,
2004; Nair et al., 2004]. Interestingly, proline-rich regions
contain several consensus PXXP motifs that may interact
with signaling proteins containing SH3 domains. Analysis
of the primary PELP1/MNAR sequence using the
Eukaryotic Linear Motif server (http://elm.eu.org) revealed
that PELP1 contained several conserved protein-protein
interaction motifs that bind to FHA, SH2, SH3, PDZ, and
WW domains. PELP1/MNAR encodes a protein of 1130
amino acids and has a predicted molecular weight of 120
kDa with an isoelectric point of 4.30, but because of its
overall negative charge and excessive number of prolines,
the protein migrates on sodium dodecyl
sulfate-polyacrylamide gel electrophoresis gels as a
160-kDa protein.
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Review  Nuclear Receptor Signaling  |  The Open Access Journal of the Nuclear Receptor Signaling AtlasFigure 1. Schematic diagram of functional domains identified in PELP1/MNAR. PXXP, SH3 binding domain; LXXLL, nuclear receptor interacting
domain; glu-rich, histone binding domain. Putative regions of interaction with other proteins are shown.
Interactions
Interactions with NRs
PELP1/MNAR appears to function as a general
coregulator, as it contains 10 NR-interacting boxes
(LXXLL) and interacts with multiple NRs. Estrogen
promotes PELP1 interaction with the AF2 domain of ERα
[Vadlamudi et al., 2001]. LXXLL motifs 4 and 5 primarily
mediate binding of PELP1/MNAR to ERα [Barletta et al.,
2004]. PELP1/MNAR also interacts with ERβ [Wong et
al., 2002]. Using receptor subtype-specific ligands,
researchers showed that PELP1/MNAR acts as a
coactivator for both ERα and ERβ [Vadlamudi et al.,
2004b]. PELP1 also interacts with several other NRs,
including androgen receptors, glucocorticoid receptors,
and progesterone receptors, in a ligand-dependent
manner [Vadlamudi et al., 2001;Wong et al., 2002].
PELP1/MNAR interacts with retinoid X receptor (RXR)α
and enhances transactivation in response to 9-cis retinoic
acid (RA) [Singh et al., 2006]. Furthermore, PELP1
functions as a corepressor of non-NR sequence-specific
transcription factors, including activating protein 1, NFκB,
and ternary complex factor/serum response factor [Choi
et al., 2004]. PELP1 also interacts with the transcription
factor signal transducer and activator of transcription
(STAT)3 and enhances growth factor-mediated STAT3
transactivation functions [Manavathi et al., 2005].
PELP1/MNAR-interacting proteins
PELP1/MNAR interacts with several components of
chromatin-modifying complexes, including CRE-binding
protein-binding protein (CBP), p300,
metastasis-associated protein (MTA)1, and histone
deacetylase 2 [Choi et al., 2004;Vadlamudi et al., 2001],
as well as with histones [Choi et al., 2004; Nair et al.,
2004]. Recent studies showed that PELP1 interacts with
Sumo-2 and forms a complex with the SET domain,
bifurcated 1 and lysine-specific demethylase 1, which are
a histone lysine methyltransferase and demethylase,
respectively [Rosendorff et al., 2006]. PELP1/MNAR also
interacts with the transcriptional activator four-and-a-half
LIM-only protein 2 [Nair et al., 2007] and with several
components of spliceosomes, including breast carcinoma
amplified sequence 2 and splicing factor 3b, indicating
that PELP1/MNAR may play a role in coupling
transcriptional activation with splicing [Nair and
Vadlamudi, 2007]. Also, PELP1/MNAR interacts with
several key components that play a role in cell cycle
progression, including CDK4, cyclin D1, and
retinoblastoma protein (pRb) [Balasenthil and Vadlamudi,
2003; Haas et al., 2005; Manavathi et al., 2005;
Vadlamudi et al., 2004b;Vadlamudi et al., 2001;Wong
et al., 2002], and with the cytosolic kinases c-Src and
phosphatidylinositol-3 kinase (PI3K) [Vadlamudi et al.,
2005b;Wong et al., 2002]. Mitogenic signaling promotes
the association of PELP1/MNAR with a number of
signaling components, including epidermal growth factor
(EGF) receptor (EGFR), HER2, STAT3, and hepatocyte
growth factor-regulated tyrosine kinase substrate (HRS)
[Rajhans and Vadlamudi, 2006].The diversity of the
PELP1/MNAR-interacting proteins (Figure 2) and the
ability of PELP1/MNAR to interact with histones and
histone-modifying components and transcriptional
regulators suggest that it plays a role in chromatin
modifications and couples NRs with different signaling
components.
Expression
PELP1/MNAR is expressed in a wide variety of tissues,
with the highest levels of expression noted in the brain,
testes, ovaries, and uterus [Greger et al., 2006; Khan et
al., 2005; Pawlak and Beyer, 2005;Vadlamudi et al.,
2001]. In the mouse brain, PELP1/MNAR expression is
developmentally regulated, and researchers have
observed widespread PELP1/MNAR expression in the
cortex, hypothalamus, and midbrain, as well as in neurons
and astroglia [Pawlak and Beyer, 2005]. In the rat brain,
a study reported high-intensity PELP1/MNAR staining in
the known targets of estrogen/steroid actions, including
the hippocampus, cortex, hypothalamus, amygdala, and
septum [Khan et al., 2005]. PELP1 expression is
developmentally regulated in mammary glands, with the
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[Vadlamudi et al., 2001]. PELP1 expression is upregulated
by estrogen signaling and differentially regulated by
selective estrogen receptor modulators [Mishra et al.,
2004a].The PELP1/MNAR promoter region contains
several consensus sites for retinoic acid receptor, and
9-cis RA transcriptionally upregulates the expression of
the PELP1 gene and PELP1 protein [Singh et al., 2006].
Figure 2. PELP1/MNAR interactome. Schematic representation of
PELP1-interacting proteins, grouped on the basis of putative function.
Cellular mechanism and cellular biology
Subcellular distribution
PELP1/MNAR contains a central consensus nuclear
localization site and exhibits both cytoplasmic and nuclear
localization, depending on the tissue [Vadlamudi et al.,
2001]. PELP1/MNAR predominantly resides in the nuclear
compartment of hormonally responsive tissues [Nair et
al., 2004;Vadlamudi et al., 2001]. Immunohistochemical
studies using a variety of mouse tissues revealed PELP1
staining in all of the tissues examined, but that PELP1
was localized differently in each organ [Vadlamudi et al.,
2001].The protein was present in both the nuclei and
cytoplasm to differing degrees, depending on the tissue.
In ovaries and fallopian tubes in pregnant mice,
PELP1/MNAR was localized predominantly in the nuclei
of cells from the corpus luteum and the epithelium of
fallopian tubes, but considerable cytoplasmic staining
also occurred in these cells. In the lung, only parts of the
epithelial cell nuclei were stained for PELP1/MNAR,
whereas in the testis, PELP1/MNAR was prominently
localized in the nuclei. Using silver-enhanced nanogold
and immunofluorescence staining of rat brain tissue,
researchers showed that PELP1/MNAR was localized
primarily in the nuclei of cells in various brain regions,
with scattered staining in the cytoplasm and plasma
membrane compartments [Khan et al., 2005]. In
endometrium, PELP1/MNAR exhibits distinct localization
depending on the phase of the endometrium. In the
proliferative and secretory phases, researchers showed
that PELP1 was expressed in both the glandular and
stromal compartments, and was localized in both the
nucleus and cytoplasm of these cells [Vadlamudi et al.,
2004b]. In contrast, in the postmenopausal phases,
researchers observed PELP1 staining only in the
glandular compartment, and that PELP1 expression was
confined to the cytoplasm of these cells [Vadlamudi et
al., 2004b]. Studies also reported PELP1/MNAR
expression in all of the cell lines commonly used in
laboratory research, including cancer cell lines; however,
the level of expression varied among the cells [Greger et
al., 2006;Vadlamudi et al., 2001]. In certain cancer cells,
researchers reported the association of a small portion
of PELP1/MNAR with the membrane [Greger et al., 2006;
Vadlamudi et al., 2005b].Within the nucleus,
PELP1/MNAR appears to be present in several
subcompartments, including the chromatin, nucleoplasm,
and nuclear matrix [Nair et al., 2004].
Posttranslational modifications
PELP1/MNAR is a phosphoprotein and is phosphorylated
on both serines/threonines and tyrosines. Bioinformatics
analysis using the Motif Scan database
(http://scansite.mit.edu/cgi-bin/motifscan_seq) indicated
that PELP1/MNAR contains several potential sites for
phosphorylation, including 8 tyrosine kinase/phosphatase
sites (recognized by EGFR, platelet-derived growth factor
receptor, insulin receptor, Src, Jak2, and SHP1) and 207
serine/threonine kinase/phosphatase motifs (recognized
by AKT, glycogen synthase kinase, CDK, casein kinase
1, casein kinase 2, LKB1, mitogen-activated protein
kinase [MAPK], protein kinase C, protein kinase A [PKA],
and proline-directed kinases). A recent study showed that
PELP1/MNAR is phosphorylated by PKA and that PKA
phosphorylates PELP1 at Ser-350, Ser-415, and Ser-613
(Nagpal and Vadlamudi, unpublished results). Another
study using phosphoproteomic analysis revealed that
PELP1/MNAR is phosphorylated at Thr-745 in the
developing brain [Ballif et al., 2004]. PELP1/MNAR
phosphorylation is modulated by hormones and growth
factor signaling. Accordingly, treatment with EGF
promotes tyrosine as well as serine phosphorylation of
PELP1 [Vadlamudi et al., 2005b]. Estrogen treatment is
shown to promote tyrosine phosphorylation of PELP1 at
Tyr920 [Greger et al., 2007].
Enzyme activity
No studies have shown an association between
PELP1/MNAR and known enzymatic activity. However,
emerging evidence suggests that PELP1/MNAR functions
as a scaffolding protein by coupling various signaling
complexes with NRs. PELP1 associates with chromatin
and interacts with histones [Nair et al., 2004]. Although
PELP1/MNAR itself has no histone acetyltransferase
activity, it can recruit other coregulators with histone
acetyltransferase activity, such as CBP and p300
[Vadlamudi et al., 2001]. In addition, PELP1/MNAR
interacts with components of histone deacetylase
complexes, including the nucleosome remodeling and
histone deacetylation complex protein MTA1 [Mishra et
www.nursa.org  NRS  | 2007 |  Vol. 5 |  DOI: 10.1621/nrs.05004 | Page 3 of 9
Review PELP1/MNAR in cell biologyal., 2003] and histone deacetylase 2 [Choi et al., 2004].
The ability of PELP1/MNAR to interact with histones,
histone acetyltransferase enzymes, and histone
deacetylase enzymes suggests that PELP1/MNAR
promotes alteration in local chromatin structure in the
vicinity of the NR target promoters by coupling NRs with
chromatin-modifying enzymes and by displacing histone
H1 [Nair et al., 2004]. A recent study also showed that
PELP1 is associated with complexes that have a histone
lysine methyltransferase and a histone lysine
demethylase, suggesting that PELP1 has some function
in these complexes [Rosendorff et al., 2006]. Furthermore,
punctate subnuclear localization and nuclear matrix
association of PELP1 suggest that PELP1 functions as
a landing platform for several other chromatin remodeling
complexes, thereby regulating gene expression. Emerging
evidence indicates that PELP1/MNAR also plays a key
role in nongenomic ER activity. PELP1/MNAR modulates
the interaction of ER with Src, stimulating Src enzymatic
activity and MAPK pathway activation [Wong et al., 2002].
Mechanistically, PELP1/MNAR interacts with the SH3
domain of c-Src via its N-terminal PXXP motif, and ER
interacts with the SH2 domain of Src at phosphotyrosine
537; the MNAR-ER interaction further stabilizes this
trimeric complex, leading to activation of the Ras/MAPK
pathway [Barletta et al., 2004]. PELP1/MNAR also directly
interacts with the p85 subunit of PI3K and enhances PI3K
activity, leading to activation of the AKT pathway
[Vadlamudi et al., 2005b].
Target genes
PELP1 does not appear to have a DNA-binding domain.
However, its ability to interact with several NRs suggests
that it enhances the transcription of target genes via its
interactions with NRs [Vadlamudi et al., 2001;Wong et
al., 2002]. Accordingly, chromatin immunoprecipitation
analysis has shown that PELP1 is recruited to the
promoters of ERα target genes, including pS2, PR, and
IGF [Nair et al., 2004]. PELP1/MNAR regulates cyclin D1
expression at the transcriptional level; such regulation
may involve functional interactions between PELP1 and
pRb [Balasenthil and Vadlamudi, 2003]. Estrogen
stimulation leads to enhanced recruitment of
PELP1/MNAR to the MTA3 promoter chromatin, implying
a role for PELP1/MNAR in the regulation of MTA3 [Mishra
et al., 2004b]. Additionally, growth factor signals promote
PELP1/MNAR interactions with STAT3; these interactions
play an important role in growth factor-mediated activation
of STAT3 target genes, including cyclin D1, fos, and jun
[Manavathi et al., 2005]. In response to 9-cis RA
stimulation, PELP1/MNAR enhances the expression of
CRBP II via its interaction with RXR [Singh et al., 2006].
Chromatin remodeling and transcriptional
activation
PELP1/MNAR exhibits a predominantly nuclear
localization in many normal tissues.Within the nuclear
compartment, PELP1 localizes to the nucleoplasm,
chromatin, and nuclear matrix and is recruited to the
promoters of several NR target genes [Nair et al., 2004].
PELP1/MNAR co-localizes with acetylated histones and
interacts with the acetyltransferases, CBP and p300, and
the PELP1/MNAR-associated histone acetyltransferase
activity increases upon ligand-based treatment [Nair et
al., 2004]. Researchers have shown reduced histone H1
residence in target gene promoters during the time that
PELP1 occupies these promoters [Nair et al., 2004].
PELP1 is also associated with deacetylases, including
components of nucleosome remodeling and the histone
deacetylation complex [Mishra et al., 2003], and inhibition
of deacetylase activity increases the PELP1 residency
time at the target gene promoter [Nair et al., 2004].
Furthermore, a recent study reported that PELP1 exists
as a complex with methyltransferases and methylases
[Rosendorff et al., 2006]. PELP1 overexpression
maintains NR-mediated nucleosomal alterations for an
extended period [Nair et al., 2004]. Collectively, these
data suggest that PELP1 contributes to alteration of the
local chromatin structure required for the optimal
transcriptional response by ligand-bound NRs via its
interactions with histones and histone-modifying enzymes.
In addition, PELP1/MNAR may play a role in NR-mediated
splicing of mRNAs [Nair and Vadlamudi, 2007].
PELP1/MNAR interacts with several components of the
spliceosome machinery, including breast carcinoma
amplified sequence 2 and splicing factor 3b, and
co-localizes with the splicing factor SC35 in nuclear
speckles. PELP1/MNAR has an RNA-binding domain,
interacts with RNA in in vitro assays, and enhances
steroid hormone-mediated splicing in minigene assays
[Nair and Vadlamudi, 2007].These emerging data
suggest that PELP1/MNAR mediates NR-mediated RNA
splicing in addition to transcriptional activation functions.
Nongenomic signaling
Evolving evidence suggests that in addition to well-studied
nuclear functions, the ERα also participates in
nongenotropic (cytoplasmic and perhaps,
membrane-mediated) signaling via formation of a
multiprotein complex involving ERα, Src kinase,
PELP1/MNAR, PI3K, SHC, and G-proteins, collectively
called the “signalsome” [Song and Santen, 2006].
Substantial evidence suggests that PELP1/MNAR
participates in cytoplasmic and membrane-mediated
signaling events through stimulation of the Src kinase,
MAPK, PI3K, and STAT3 [Manavathi and Kumar, 2006].
Emerging evidence suggests that PELP1/MNAR is one
of the coregulators that facilitate NR interactions with
cytoplasmic signaling components [Rajhans and
Vadlamudi, 2006;Vadlamudi et al., 2004b]. Researchers
initially identified PELP1/MNAR as a Src SH2-binding
protein [Joung et al., 1996], and some portion of
PELP1/MNAR exists in the cytoplasm and at the
membranes [Nair et al., 2004;Vadlamudi et al., 2004b].
PELP1/MNAR modulates ER’s interaction with c-Src,
stimulating c-Src enzymatic activity and leading to
activation of the mitogen activated protein kinase (MAPK)
pathway [Wong et al., 2002]. Mutational analysis of ERα
and c-Src mutants revealed that MNAR interacts with the
c-Src SH3 domain via its N-terminal PXXP motif. ERα
interacts with Src’s SH2 domain at phosphotyrosine 537,
and the MNAR-ER interaction further stabilizes this
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with the p85 subunit of PI3K and enhances PI3K activity
[Vadlamudi et al., 2005b]. A recent study reported direct
correlation between MNAR expression levels and
E2-induced activation of PI3 and Akt kinases. In their
model system, E2 treatment induced complex formation
of endogenous MNAR, ERα, c-Src, and p85, the
regulatory subunit of PI3 kinase.The interaction between
p85 and MNAR required activation of c-Src and MNAR
phosphorylation on Tyr920.These results suggest that
PELP1/MNAR plays a key role in the E2-induced
regulation of cell proliferation and apoptosis via its
regulation of the PI3K-AKT pathway [Greger et al., 2007].
EGF promotes PELP1/MNAR association with the EGFR,
resulting in the tyrosine phosphorylation of PELP1/MNAR
[Vadlamudi et al., 2005b]. PELP1/MNAR can enhance
EGF-mediated ERα transactivation, and mislocalization
of PELP1/MNAR in the cytoplasm can increase ERα
basal activity via the EGFR and PI3K pathways. Using a
yeast two-hybrid screen, [Rayala et al., 2006a]
demonstrated the physiological interaction between HRS
and PELP1/MNAR. Interestingly, HRS sequesters
PELP1/MNAR in the cytoplasm, leading to
EGFR-dependent activation of MAPK. PELP1/MNAR can
interact with several growth factor signaling components,
including STAT3, and may have important functional
implications in ERα/growth factor crosstalk [Vadlamudi
et al., 2005b].
Cell cycle progression
Evidence suggests that PELP1/MNAR contributes to
E2-mediated G1/S-phase progression [Balasenthil and
Vadlamudi, 2003]. In this study, overexpression of
PELP1/MNAR in breast cancer model cells was
accompanied by persistent hyperphosphorylation of the
cell cycle switch protein pRb in an E2-dependent manner,
with increases in the rate of cell proliferation.
PELP1/MNAR interacts with pRb via its C-terminal pocket
domain, and PELP1/pRb interactions play a role in the
maximal activation of E2 target genes such as cyclin D1.
The results of this study suggested that PELP1/MNAR
positively contributes to E2-mediated G1/S-phase
progression and plays a permissive role in E2-mediated
cell cycle progression, presumably via its regulatory
interactions with the pRb pathway. Increased
PELP1/MNAR expression in a mammary gland during
pregnancy, when the rate of cell proliferation is high,
supports a physiological role for PELP1/MNAR in
E2-mediated cell cycle progression in mammary glands
[Vadlamudi et al., 2001]. In addition to mitosis, emerging
evidence indicates that PELP1/MNAR plays a role in
meiosis. For example, in Xenopus oocytes, PELP1/MNAR
interacts with androgen receptor (AR) and appears to
mediate inhibition of meiosis via Gβγ signaling.
PELP1/MNAR is widely expressed in oocytes, and
reduction of its expression by RNA interference markedly
enhances testosterone-triggered maturation and activation
of MAPK. Furthermore, PELP1/MNAR appears to
participate in maintaining meiotic arrest by directly
enhancing G-mediated inhibition of meiosis and androgen
binding to AR, releasing this inhibition, which allows
maturation to occur [Haas et al., 2005].
Apoptosis and differentiation
PELP1/MNAR also appears to participate in cellular
differentiation. In one study, PELP1/MNAR potentiated
the effects of 9-cis RA and peroxisome
proliferator-activated receptor (PPAR)-specific ligands by
functioning as a coactivator of RXR homodimers and
RXR-PPAR heterodimers [Singh et al., 2006].
Furthermore, the ligand 9-cis RA transcriptionally
upregulated expression of the PELP1/MNAR gene.
Functioning as a coactivator of the RXR-PPAR
heterodimer, PELP1 was able to potentiate the
differentiation-inducing effects of PPAR ligand, suggesting
a novel facet of PELP1/MNAR function as a potentiator
of antiproliferative and differentiation effects of
RXR-specific ligands and PPAR-specific ligands. Because
nongenomic functions of NRs are implicated in different
cellular processes, including cell survival and apoptosis,
PELP1/MNAR-mediated nongenomic actions may also
play a role in PELP1-mediated apoptosis and
differentiation.
Disease
Oncogenesis
Emerging evidence suggests that PELP1/MNAR has
tumorigenic potential. PELP1/MNAR interacts with and
modulates functions of several proto-oncogenes, including
c-Src, STAT3, and EGFR [Rajhans and Vadlamudi, 2006].
In a recent study, PELP1 deregulation was shown to
promote cell transformation in NIH3T3 fibroblast
cell-based focus formation assays [Rajhans and
Vadlamudi, 2006]. PELP1/MNAR also enhances the
transformation potential of c-Src and other
proto-oncogenes in focus formation assays. Similarly,
PELP1-transfected (but not vector-transfected) rat kidney
epithelial RK3E cells exhibited transformation potential.
A PELP1 mutant that uniquely localizes in the cytoplasm
also demonstrated focus formation, although to a lesser
degree than that of PELP1-WT [Rajhans, In Press].
Vector-transfected RK3E cells are incapable of promoting
anchorage-independent growth and the
PELP1-WT-transfected RK3E cells showed a significant
increase in colony formation. In addition, PELP1/MNAR
promotes anchorage-independent growth of breast cancer
cells in soft agar assays [Rajhans, In Press;Vadlamudi
et al., 2005b]. In these studies, when injected
subcutaneously into the mammary fat pad of mice in the
absence of treatment with exogenous E2, MCF-7 human
breast cancer cells stably expressing PELP1 showed
tumor formation in 50% of the injected sites.These results
suggest that deregulation of PELP1/MNAR expression
is sufficient to promote hormone-independent growth of
MCF-7 cells. Accordingly, PELP1/MNAR is widely
expressed in breast cancer cells [Greger et al., 2006;
Vadlamudi et al., 2001], and PELP1 expression and
localization are deregulated in breast tumors [Vadlamudi
et al., 2004a;Vadlamudi et al., 2001]. Also, PELP1/MNAR
expression and localization are widely deregulated in
endometrial cancers [Vadlamudi et al., 2004b]. In addition,
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Review PELP1/MNAR in cell biologyFigure 3. Schematic representation of the current understanding of the PELP1/MNAR signaling pathway. PELP1 participation in multiple
stages of nuclear receptor (genomic and nongenomic) signaling pathways suggests that PELP1 deregulation likely contributes to the development of
hormonal independence, tumorigenesis and metastasis.
PELP1/MNAR and ERα are localized predominantly in
the cytoplasm in high-grade endometrial tumor cells,
suggesting that PELP1/MNAR deregulation plays a role
in endometrial cancer progression [Vadlamudi et al.,
2004b]. Ongoing studies using human ovarian cancer
tissue arrays have revealed that PELP1 is overexpressed
twofold to threefold in 60% of ovarian tumors. PELP1 is
deregulated in several ovarian tumor subtypes, including
serous tumors, endometrioid tumors, clear cell
carcinomas, and mucous tumors, and is predominantly
localized in the cytoplasm in ovarian tumors (Chakravarty
and Vadlamudi, unpublished results). Salivary duct
carcinoma is a high-grade neoplasm with a morphology
similar to that of mammary duct carcinoma. Interestingly,
these tumors express PELP1/MNAR and ERα, and
PELP1/MNAR signaling may therefore play a role in
salivary tumorigenesis [Vadlamudi et al., 2005a]. Also,
researchers reported elevated PELP1/MNAR expression
in high-grade prostate tumors [Nair et al., 2007]. In that
study, PELP1/MNAR staining was predominantly localized
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expression was correlated with increased prostate tumor
grade.
Role of PELP1 in metastasis
PELP1/MNAR interacts with several proteins involved in
cytoskeleton remodeling, including Src kinase, PI3K, and
four-and-a-half LIM-only protein 2, and participates in
E2-mediated nongenomic signaling pathways [Gururaj
et al., 2006;Vadlamudi et al., 2005b;Wong et al., 2002].
Also, PELP1/MNAR overexpression uniquely enhances
E2-mediated ruffles and filopodium-like structures. A
recent study showed that in Boyden chamber assays,
PELP1/MNAR-overexpressing MCF-7 cells displayed
increased cell motility upon treatment with E2, whereas
knockdown of PELP1/MNAR expression by small
interfering RNA substantially reduced E2-mediated cell
motility compared with that in control MCF-7 cells
[Rajhans, In Press]. PELP1 modulates functions of MTA1,
a protein implicated in metastasis. PELP1/MNAR also
interacts with the MTA1-associated coactivator and
promotes ERα-transactivation functions in a synergistic
manner [Mishra et al., 2003]. Additionally, PELP1/MNAR
modulates expression of MTA3, a gene implicated in the
invasive growth of human breast cancers.The ability of
PELP1/MNAR to recruit to the MTA3 promoter chromatin
[Mishra et al., 2004b] and its interactions with other MTA
family members, suggest that deregulation of
PELP1/MNAR expression promotes metastasis. A recent
study measured the expression levels of PELP1 by IHC
examination and the results showed that when compared
with node-negative specimens, node-positive and
metastatic tumors exhibited increased PELP1 expression
[Rajhans, In Press]. Statistical analysis revealed that
PELP1 expression was positively correlated with cancer
grade and node status.The number of samples with a
high level (score 3) of PELP1 staining increased as
tumors progressed from grade 1 to grade 2 or 3 (P =
0.005). Similarly, node-positive and metastatic tumors
exhibited a greater expression of PELP1 than did
node-negative tumors (P = 0.003). No significant
correlation of PELP1 expression with ER, PR, patient
age, or tumor stage was observed.These results suggest
that PELP1 expression may be altered in higher grade
node-positive and metastatic tumors [Rajhans, In Press].
The ability of PELP1/MNAR to interact with various
enzymes that modulate the cytoskeleton and its
deregulation in metastatic breast tumors suggest that
PELP1/MNAR signaling plays a role in tumor cell
migration and metastasis.
Role in hormonal independence
Although PELP1/MNAR is predominantly localized in the
nuclei of hormonally responsive tissue cells, in one study
it was shown to be localized in either the cytoplasm alone
or the cytoplasm and nuclei in 58% of
PELP1/MNAR-positive breast tumor cells [Vadlamudi et
al., 2005b]. In that study, cells that mimicked
PELP1/MNAR cytoplasmic localization in tumors were
hypersensitive to E2, but resistant to tamoxifen. Altered
localization of PELP1/MNAR to the cytoplasm was
sufficient to trigger its interaction with the p85 subunit of
PI3K, leading to activation of PI3K [Vadlamudi et al.,
2005b]. Furthermore, PELP1/MNAR exhibits
phase-dependent localization and expression in the
endometrium and enhances tamoxifen-mediated partial
agonist signaling in endometrial cancer cells [Vadlamudi
et al., 2004b].The normal, cytoplasmic localization of
PELP1/MNAR in the endometrium of postmenopausal
women suggests that PELP1/MNAR-mediated
nongenomic functions may play a role in endometrial cell
survival under low estrogen conditions. However, its
exclusive cytoplasmic localization, as seen in a subset
of breast cancer cells, may provide survival advantage
to the cancer cells, and thus may contribute to tumorigenic
potential. Furthermore, cytoplasmic PELP1/MNAR is also
shown to interact with the trafficking molecule HRS to
activate MAPK in the presence of EGFR [Rayala et al.,
2006a]. In another study, clones of MCF-7 cells
overexpressing cytoplasmic PELP1/MNAR were more
sensitive to tumor necrosis factor-α-induced apoptosis
than cells expressing wild-type nuclear PELP1/MNAR
[Rayala et al., 2006b].The results of this study suggest
that altered localization of PELP1/MNAR modulates the
hormonal sensitivity of breast cancer cells, thus paving
the way for development of new treatment strategies for
breast tumors with cytoplasmic PELP1 expression.
Deregulation of PELP1/MNAR expression increases the
expression of aromatase, an enzyme that produces
estrogen locally [Rajhans and Vadlamudi, 2006]. Recent
data suggest that AR, PELP1/MNAR, and Src form
constitutive complexes in prostate cancer model cells
that exhibit androgen independence, and constitutive
activation of the Src/MAPK kinase 1/2/extracellular
signal-related kinase 1/2/CRE-binding protein pathway
is associated with the androgen-independence phenotype
[Unni et al., 2004].The mechanisms or modifications that
promote PELP1 localization to the cytoplasm remain
elusive. Since emerging evidence suggests that
coregulator posttranslational modification may play a role
in their localization, it is tempting to speculate that
posttranslational modification of PELP1/MNAR may play
a role in its exclusive cytoplasmic localization.Thus,
deregulation of PELP1/MNAR expression has the
potential to contribute to the hormonal therapy resistance
seen in patients with hormone-dependent cancers by
excessively activating nongenomic signaling pathways.
Summary
PELP1/MNAR appears to function as a scaffolding
protein, coupling NRs with several proteins implicated in
oncogenesis (Figure 3).With the enormous potential of
PELP1/MNAR as a modulator of NRs and oncogenes,
deregulation of PELP1/MNAR expression is likely to
provide cancer cells with a survival, growth, metastasis,
and hormonal independence advantage. However, the
mechanism or mechanisms by which PELP1/MNAR
promotes these functions are not clear. PELP1/MNAR
functions appear to be regulated by a variety of binding
proteins and by posttranslational modifications. Future
studies elucidating the molecular mechanism or
mechanisms of action of PELP1/MNAR in normal and
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Review PELP1/MNAR in cell biologytumor cells, characterizing the physiological function of
PELP1/MNAR using Tg/KO mouse models, identifying
PELP1/MNAR target genes, and profiling the expression
of PELP1/MNAR in large numbers of tumor samples
would allow use of this NR coregulator protein as a novel
therapeutic target.
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